Global Plasma Fractionation Market to Generate $56,870.10 Million by 2031, Owing to An Increase in Use of Immunoglobulin for Treatment of Various Diseases

Plasma fractionation is a technique used to separate the different components and compounds present in blood plasma. These compounds, primarily plasma proteins, are then used to produce therapeutic products which can be administered to the patient for better targeting of the ailment. Plasma fractionation is done either by changing the chemical properties of the plasma proteins or through mechanical processes like depth filtration, centrifugation, or chromatography.

Forecast Analysis of the Plasma Fractionation Market

In recent years, growing use of immunoglobulin to treat conditions such as immunodeficiency diseases, idiopathic thrombocytosis purpura (ITP), Kawasaki disease, and nervous system disorders is expected to be the primary growth driver of the global plasma fractionation market in the forecast years. Along with this, government initiatives and rising investments in R&D are anticipated to offer numerous investment and growth opportunities to the market in the analysis timeframe. Additionally, the growing risk of inflammatory disorders in people is anticipated to push the market higher in the 2022-2031 period. However, growing use of recombinant therapies as an alternative to plasma-driven medicines may restrain the growth of the plasma fractionation market in the forecast period.

Regionally, the plasma fractionation market in the North America region is expected to be the most dominant one by 2031. The rise in the prevalence of various genetic diseases and the growth of geriatric population are projected to be the two main factors behind the growth of the market in this region.

According to the report published by Research Dive, the plasma fractionation market is expected to gather a revenue of $56,870.10 million by 2031 and grow at 7.2% CAGR in the 2022–2031 timeframe. Some prominent market players include Kedrion S.P.A, CSL Behring, Takeda Pharmaceutical Company Limited, Octapharma AG, Grifols, S.A., Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings, Inc., LFB Group, and Japan Blood Products Organization, and many others.

Covid-19 Impact on the Plasma Fractionation Market

The outbreak of the Covid-19 pandemic has had a massive negative effect on almost all industries and businesses across the world. The plasma fractionation market, too, faced a similar fate. The overall demand for plasma fractionation decreased in the pandemic due to reduction in the number of blood donations and plasma collections. Moreover, many elective surgeries were postponed during the pandemic which further reduced the demand for plasma fractionation. All these factors brought down the growth rate of the market.

Key Developments of the Plasma Fractionation Market

The significant companies operating in the industry are adopting numerous growth strategies & business tactics such as partnerships, collaborations, mergers & acquisitions, and launches to maintain a robust position in the overall market, thus helping the plasma fractionation market to flourish. For instance:

• In July 2020, Grifols, a global pharmaceuticals company, announced the acquisition of a Green Cross plasma fractionation facility in Montreal from GC Pharma (Group), another leading pharmaceutical company. This acquisition is expected to help Grifols to scale up their operations globally in the near future.
   
• In March 2023, Takeda, a pharmaceutical firm, announced its investment of 100 billion Japanese Yen in a new plasma fractionation facility in Osaka, Japan. This is Takeda’s largest investment in plasma-derived therapies and is expected to help the company to cater to the demands of the medical sector comprehensively.